MAPT and dementia: Regardless of this debate, Braak’s studies and many others have confirmed a key fact: phosphorylated tau (p-tau) deposition in the brain precedes the clinical onset of mild cognitive decline and dementia, and several biomarkers in cerebrospinal fluid or plasma precede clinical manifestations of cognitive decline or dementia.